Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Pfizer Inc. $PFE

Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, Holdings Channel.com reports. The fund bought 76,957 shares of the biopharmaceutical company’s stock, valued at approximately $1,916,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after acquiring an additional 7,031,162 shares during the last quarter. State Street Corp increased its position in shares of Pfizer by 0.9% in the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after buying an additional 2,786,098 shares in the last quarter. Northern Trust Corp increased its position in shares of Pfizer by 1.4% in the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after buying an additional 869,175 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Pfizer by 1.9% in the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after buying an additional 897,786 shares in the last quarter. Finally, Legal & General Group Plc increased its position in shares of Pfizer by 8.6% in the 3rd quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock valued at $1,063,565,000 after buying an additional 3,296,415 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.5%

Pfizer stock opened at $25.93 on Friday. The firm has a 50-day moving average of $26.88 and a 200-day moving average of $26.23. Pfizer Inc. has a one year low of $22.81 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company has a market cap of $147.76 billion, a price-to-earnings ratio of 19.79 and a beta of 0.35.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period last year, the business posted $0.92 EPS. Pfizer’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced strong Phase 2 results for its investigational 25-valent pneumococcal vaccine in infants, including a stronger immune response than Prevnar 20 and up to 15-fold higher antibody levels against a key strain. The company is now moving the program into pivotal Phase 3 testing, which could support future vaccine growth. Article Title
• Positive Sentiment: The company also received a broader European indication for HYMPAVZI, adding another recent R&D win that may strengthen Pfizer’s hemophilia franchise and improve investor confidence in the pipeline. Article Title
• Positive Sentiment: Pfizer and Rigel Pharmaceuticals expanded a commercialization deal for VEPPANU (vepdegestrant), creating another potential partnership-driven revenue stream tied to oncology. Article Title
• Positive Sentiment: Pfizer’s oncology growth story is also getting attention, with coverage pointing to Padcev, biosimilars, and late-stage pipeline assets as key long-term drivers. Article Title
• Neutral Sentiment: Pfizer was also listed as a participant in an AI industry summit, but this appears unrelated to the company’s core investment thesis and is unlikely to move the stock on its own. Article Title

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent analyst reports. Citigroup upped their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. UBS Group upped their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research report on Monday, April 13th. Guggenheim upped their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. Finally, Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.61.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.